Cetuximab (anti-EGFR)

CAS No. 205923-56-4

Cetuximab (anti-EGFR)( C225 )

Catalog No. M21142 CAS No. 205923-56-4

Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 275 In Stock
5MG 458 In Stock
10MG 662 In Stock
25MG 1036 In Stock
50MG 1367 In Stock
100MG 1841 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cetuximab (anti-EGFR)
  • Note
    Research use only, not for human use.
  • Brief Description
    Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
  • Description
    Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    C225
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    cancer
  • Indication
    Colorectal Cancer

Chemical Information

  • CAS Number
    205923-56-4
  • Formula Weight
    2756.23
  • Molecular Formula
    C107H179N35O36S7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Huang S M Bock J M Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation Apoptosis and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res 1999 59(8):1935-1940.
molnova catalog
related products
  • Daphnetin

    Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.

  • Mutated EGFR-IN-1

    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.

  • AST-1306

    AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.